Switching patients with Crohn disease from reference adalimumab to SB5, a Samsung Bioepis biosimilar, did not lead to major changes in disease activity in a real-world analysis.
Patients with Crohn disease who were switched from reference adalimumab (Humira; AbbVie) to Samsung Bioepis’ adalimumab biosimilar (SB5) did not experience any major differences in disease activity, suggesting that switching to a biosimilar was safe and tolerable.
The results were part of the PROPER study, an interim analysis assessing real-world use of SB5 after transition from the reference product in a Crohn disease-specific population, and were presented during the European Crohn’s and Colitis Organization’s 2022 annual meeting, the company said in a statement to The Center for Biosimilars®.
SB5 received marketing authorization in the European Union, where it is marketed under the name Imraldi, in August 2017. It was also approved by the FDA in July 2019 under the name Hadlima, where it will be marketed through a commercialization agreement between Republic of Korea–based Samsung Bioepis and Organon, a Merck spin-off company based in New Jersey. In January 2022, the 2 companies announced that they would pursue regulatory approval for a high-concentration, citrate-free formulation of Hadlima.
Although the original SB5 formulation has been on the market in Europe since receiving authorization, it is not permitted for US market introduction until 2023, the year when adalimumab biosimilars will legally be allowed on the market. There are 9 authorized adalimumab biosimilars in the European Union and 7 FDA-approved products in the United States.
The approvals were based on preclinical and clinical phase 1 and phase 3 studies that demonstrated that the biosimilar had comparable safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product.
The PROPER study included patients with immune-mediated inflammatory disease who were receiving treatment at 32 specialty centers in Belgium, Germany, Ireland, Italy, Spain, and the United Kingdom. Eligible patients were transitioned to SB5 following a minimum of 16 weeks of treatment with Humira. The data were retrospectively collected from patient charts from 24 weeks prior to 48 weeks after the initiation of treatment with SB5. The data extract date was October 5, 2021.
In total, 462 patients were enrolled in the analysis, with a mean (SD) age of 43.5 (14.0) years, and 46% were women. The majority of the cohort was from Germany (n = 127), followed by Spain (n = 118), Italy (n = 79), Belgium (n = 56), Ireland (n = 46), and the United Kingdom (n = 36). At the time of data collection, 416 patients had completed 48 weeks of follow-up and 15 patients withdrew from the study.
The most common reasons that patients switched away from the reference product were physician decision and a mandate from a health authority or payer. At baseline, most of the patients were in remission or had mild disease but were considered to be in remission or have a stable condition according to a physician.
Overall, in 24 patients, 27 serious adverse events were reported, of which 4 were considered to be related to the SB5 therapy. Treatment-related events included 1 case of anal fistula, 2 cases of perianal abscesses, and 1 case of subileus. The investigators determined that no new safety concerns were detected.
Reference
Dignass AU, Gisbert JP, Bossa F, Freudensprung U, Addison J. The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease. Presented at: ECCO 2022; February 16-19, 2022; Virtual. Abstract P434.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.